Skip to content

Clinical Study of Huamoyan Granules in Treating Acute and Chronic Knee Joint Synovitis

Randomized, double-blinded, placebo parallel control, multi-center clinical study of Huamoyan Granules in Treating Acute and Chronic Knee Joint Synovitis(Dampness-heat blocking collaterals)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003025
Enrollment
Unknown
Registered
2013-01-24
Start date
2013-01-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute and Chronic Knee Joint Synovitis

Interventions

Huamoyan Granules:One sachet each time, three times a day, taken with water
Control:Placebo

Sponsors

Shanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Volunteer to join in the experiment and sign the letter of consent; (2) Age between 18 to 70 years, both male and female; (3) Comply with the diagnosis standard of knee joint synovitis; (4) Comply with differentiation standard of dampness-heat blocking collaterals syndrome; (5) Grading medical image of K-L knee-joint is less than or equal to 3 scores; (6) Average scores of knee-joint pain are between 40 and 70 scores; (7) Course of treatment for acute period is less than or equal to 14 days; Course of treatment for chronic period is more than 14 days.

Exclusion criteria

Exclusion criteria: (1) Diagnosed as dampness and rheumatism or deficiency cold of spleen and stomach; (2) Ready to be pregnant, pregnancy or breasting feeding woman; (3) Diabetic patient; (4) Patients with allergic constitution or allergic to ingredients of test drug; (5) Accompanied with knee osteoarthritis without swollen; blood stagnation in kneel; rheumatic arthritis or rheumatoid arthritis; inflectional arthritis; gout arthritis; synovial tuberculosis; synovioma; hemophilic arthritis; bone tumor; Pigmented villonodular synovitis; thyroid hyperfunction; Osteomalacia;multiple myeloma patients; (6) Patients with drug abuse or alcoholism history, psychiatric history, alzheimer; (7) Accompanied with severe primary disease including heart and cerebral disease, liver, kidney and hematopoietic system; (8) ALT, AST, Cr are more than normal value; (9) Patients with critical severe disease, beyond assessment of efficiency and safety of drug. (10) Patients take other drug to treat synovitis within 3 months before the experiment, take cortin within one week before the experiment. Patients take acupuncture, and physical method to treat disease within one week before the experiment. Patients take some medicine which will effect efficiency and safety in long term and accept comprehensive treatment; (11) Join in other clinical experiment within 3 months before this experiment; (12) Other unqualified patients specified by researchers.

Design outcomes

Primary

MeasureTime frame
Knee joint swelling point;

Countries

China

Contacts

Public ContactJinxue Wang
wangjinxue0901@126.com+86 13601168718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026